Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
ANZ Fertility Services Market Trends & 2033 Outlook
Australia & New Zealand Fertility Services Market
ANZ Fertility Services Market Trends & 2033 Outlook
Australia & New Zealand Fertility Services Market by Procedure (IVF with ICSI, IUI, IVF without ICSI, Surrogacy, Others), by Service (Fresh Non-Donor, Frozen Non-Donor, Egg & Embryo Banking, Fresh Donor, Frozen Donor), by End User (Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034
Updated On : Oct 7, 2026|Base Year : 2025|Pages : 104
Key Insights & Executive Summary: Australia & New Zealand Fertility Services Market
Australia & New Zealand Fertility Services Market Size (In Million)
1.5B
1.0B
500.0M
0
971.0 M
2025
1.016 B
2026
1.063 B
2027
1.112 B
2028
1.163 B
2029
1.216 B
2030
1.272 B
2031
Market at a Glance
The Australia & New Zealand fertility services market is valued at USD 971.33 million in 2025 and is projected to reach USD 1,392.0 million by 2033, expanding at a 4.6% CAGR. Growth is structural rather than cyclical: the median age of first birth in Australia has moved beyond 31 years, and single women and same-sex couples now represent a growing share of treatment starts.
Procedure mix: the IVF with ICSI Market absorbs the largest single revenue pool in the region, followed by IUI and standard IVF cycles; ICSI pricing sets the benchmark against which every other procedure line is discounted.
Service mix: frozen embryo transfer cycles now exceed fresh transfers in most Australian clinics, pushing the Frozen Non-Donor and Egg & Embryo Banking Market lines to a combined majority of service revenue.
End-user mix: the Fertility Clinics Market controls the bulk of treatment delivery, while the Hospital Fertility Services Market handles tertiary, publicly funded and complex surgical cases.
Reimbursement: Australia's Medicare Benefits Schedule and Extended Medicare Safety Net cap out-of-pocket costs for eligible patients, while New Zealand funds a defined number of public cycles per eligible couple.
Capacity: accredited embryology laboratory throughput, not clinician supply, is the binding constraint on regional volume growth.
The Assisted Reproductive Technology Market in ANZ is consolidating around three to four multi-site groups. Consolidation compresses consumable costs per cycle but increases concentration risk in referral networks, particularly in metropolitan Sydney, Melbourne and Auckland.
Segment Deep-Dive: IVF with ICSI Dominance in Australia & New Zealand Fertility Services Market
Segment Analysis Matrix
Segment
CAGR (%)
Market Share (%)
Key Demand Driver
IVF with ICSI
5.2
46
Male-factor infertility diagnosis and higher fertilisation certainty
Egg & Embryo Banking Market
6.8
11
Elective and onco-fertility preservation demand
IUI Treatment Market
3.4
14
Lower-cost first-line treatment and donor sperm access
Why ICSI Leads
ICSI is attached to roughly 46% of stimulated cycles in Australia, well above the global average, because male-factor infertility accounts for a large share of presenting diagnoses.
The procedure carries a price premium of AUD 400–900 per cycle over standard IVF, which lifts blended revenue per patient without adding laboratory hours.
Demand is less price-elastic than IUI because ICSI is typically recommended after failed first-line treatment, not as an entry point.
Sub-Segment Dynamics
Frozen Non-Donor cycles are the fastest-scaling service line, supported by vitrification protocols and single-embryo transfer policy.
Egg & Embryo Banking is growing at 6.8%, the highest rate in the segment set, driven by elective preservation among women aged 32–38 and by onco-fertility referrals.
Fresh Donor and Frozen Donor lines remain capacity-constrained by donor gamete availability rather than by clinical demand.
The Preimplantation Genetic Testing Market is increasingly bundled into the ICSI pathway, with PGT-A offered on roughly 25–30% of blastocysts in private Australian clinics.
Margin Pressure
Public funding caps in New Zealand and the Medicare safety net in Australia compress headline pricing, so clinic gross margins depend on consumable cost control and cycle throughput.
Consumables and pharmaceuticals represent an estimated 30–38% of direct cost per stimulated cycle, leaving thin headroom when imported media and gonadotropin prices rise.
Smaller single-site operators face the steepest pressure because they cannot negotiate volume-based supply contracts or absorb laboratory accreditation costs as easily.
Primary Market Drivers & Growth Restraints in Australia & New Zealand Fertility Services Market
Market Dynamics Impact Analysis
Factor Type
Description
Impact Level
Timeline
Driver
Rising female age at first birth (median above 31 years) expands the diagnosed infertile population
High
Long term
Driver
Employer-funded fertility benefits and expanded rebate coverage improve affordability
High
Short term
Driver
Regulated donor gamete import pathways widen treatment eligibility for single and same-sex patients
Medium
Medium term
Restraint
Out-of-pocket cost of AUD 8,000–12,000 per self-funded cycle suppresses repeat treatment
High
Long term
Restraint
Embryologist and sonographer shortages limit accredited laboratory capacity
High
Medium term
Restraint
Import dependence on culture media and gonadotropins exposes clinics to currency and freight shocks
Medium
Short term
Quantitative Read on Catalysts
Female age at treatment start is the strongest single predictor of cycle demand; every additional year in median maternal age correlates with measurably higher ART utilisation per 1,000 women.
Corporate fertility benefit programmes now cover employees at several large Australian employers, shifting a portion of cost from households to insurers and improving the conversion rate from first consultation to first cycle.
Regulatory liberalisation of donor gamete importation and reciprocal recognition of accredited gamete banks has expanded the eligible patient pool without requiring new domestic donor recruitment.
Bottlenecks to Watch
Training pipelines for clinical embryologists take 3–5 years, so laboratory staffing, not capital, determines how quickly the Fertility Clinics Market can scale.
Public funding in New Zealand is rationed by eligibility criteria and waiting lists, capping the publicly financed share of national cycle volume.
Currency exposure on euro- and USD-denominated supply contracts remains the most volatile cost line per cycle.
Competitive Ecosystem & Key Vendor Profiles: Australia & New Zealand Fertility Services Market
Vendor Benchmarking Matrix
Company Name
Core Strength
Target Audience
Market Position
MONASH IVF GROUP LIMITED
Largest accredited laboratory network in Australia
Insured and self-funded private patients
Leader
VIRTUS HEALTH
Multi-brand clinic footprint across ANZ and Europe
Private patients and day-surgery partners
Leader
GENEA LIMITED
In-house culture media and time-lapse incubation IP
High-complexity IVF patients
Leader
FERTILITY ASSOCIATES LIMITED
Publicly contracted New Zealand service delivery
Publicly funded NZ patients
Leader
CARE FERTILITY
Reproductive genetics and PGT capability
Genetic screening referrals
Challenger
CITY FERTILITY
Transparent cycle pricing and metro clinic density
Price-sensitive metropolitan patients
Challenger
ADORA FERTILITY
Low-cost, high-volume IVF model
Out-of-pocket patients
Challenger
FERTILITY SA
Deep regional referral relationships in South Australia
Regional patients
Niche
FERTILITY FIRST
Evidence-led minimal-stimulation protocols
Patients seeking low-intervention care
Niche
NATIONAL WOMEN'S HEALTH
Hospital-integrated tertiary reproductive care
Public hospital patients
Niche
Strategic Profiles
MONASH IVF GROUP LIMITED: Operates the widest network of accredited embryology laboratories in Australia and uses that scale to negotiate consumable pricing that single-site clinics cannot match.
VIRTUS HEALTH: Runs a multi-brand portfolio that lets it serve distinct patient price points from one shared laboratory and diagnostic backbone.
GENEA LIMITED: Differentiates through vertical integration into culture media and time-lapse incubation hardware, reducing dependence on third-party supply.
FERTILITY ASSOCIATES LIMITED: Holds a substantial share of New Zealand publicly funded cycles and therefore carries direct exposure to government funding decisions.
CARE FERTILITY: Competes on reproductive genetics depth, positioning PGT capability as its primary referral hook.
CITY FERTILITY: Keeps list pricing visible and simple, targeting patients who comparison-shop on total out-of-pocket cost.
ADORA FERTILITY: Applies a high-volume, low-margin model that undercuts traditional private pricing by a wide margin.
FERTILITY SA: Maintains referral depth in South Australia and adjacent regional catchment areas.
FERTILITY FIRST: Markets low-intervention and minimal-stimulation pathways to patients wary of aggressive protocols.
NATIONAL WOMEN'S HEALTH: Anchors public hospital reproductive services and handles medically complex referrals.
Strategic Milestones & Recent Developments in Australia & New Zealand Fertility Services Market
Latest Strategic Moves
Date
Company
Event Type
Impact
2022
VIRTUS HEALTH
M&A
Consortium take-private valued the group in the region of AUD 695 million, consolidating multi-brand ownership
2023
MONASH IVF GROUP LIMITED
Expansion
Added day-hospital and diagnostic capacity to support higher ICSI and frozen transfer volumes
2023
GENEA LIMITED
Launch
Commercialised next-generation culture media and time-lapse incubation lines to reduce protocol variability
2024
FERTILITY ASSOCIATES LIMITED
Partnership
Extended publicly funded treatment pathways with New Zealand district health providers
2024
CARE FERTILITY
Partnership
Broadened PGT referral links with metropolitan genetics laboratories
2025
Sector-wide accreditation bodies
Policy
Updated laboratory quality and donor record-retention expectations for accredited clinics
Chronology of Key Moves
2022: The Virtus Health take-private was the largest ownership change in the ANZ sector, concentrating several clinic brands under one capital structure and triggering peer revaluation.
2023: Monash IVF's capacity additions targeted the bottleneck that matters most — laboratory and day-surgery throughput rather than clinician recruitment.
2023: Genea's media and incubation launch pushed vertical integration further upstream, reducing reliance on imported consumables.
2024: Fertility Associates' public-pathway expansion reinforced New Zealand's position as a predominantly publicly funded market.
2025: Accreditation updates on quality indicators raise the fixed compliance cost per clinic, favouring networks over single-site operators.
Regional Market Analysis & Growth Corridors for Australia & New Zealand Fertility Services Market
Regional Growth Comparison
Region
Projected CAGR (%)
Base Year Valuation (2025)
Primary Catalyst
Regulatory Stringency
Asia-Pacific
5.1
USD 9.4 Billion
Private clinic expansion and high treatment volume in China, India and Japan
Moderate to high
Europe
3.8
USD 7.1 Billion
Broad public reimbursement and cross-border patient mobility
High
North America
4.2
USD 6.2 Billion
High revenue per cycle and employer-funded fertility benefits
High
Middle East & Africa
6.3
USD 2.4 Billion
New private clinic capacity and medical tourism in the GCC
Emerging to moderate
South America
5.4
USD 2.0 Billion
Self-pay growth and expanding laboratory accreditation
Moderate
Fastest-Growing versus Most Mature
Middle East & Africa posts the highest projected CAGR at 6.3%, but from a small base and with uneven laboratory accreditation.
Asia-Pacific is the largest and second-fastest bloc at 5.1%; Oceania contributes only a modest share of volume but among the highest revenue per cycle globally.
Europe is the most mature market at 3.8%, constrained by reimbursement ceilings and stable demographic demand.
North America converts high unit pricing into value growth at 4.2%, with employer benefit mandates doing more work than volume expansion.
Oceania Corridor Detail
Within the region, metropolitan Sydney, Melbourne and Auckland account for the majority of ANZ cycle volume, with regional clinics dependent on fly-in specialist coverage.
New Zealand's funding model caps public cycle access, so private out-of-pocket demand absorbs any excess waiting-list pressure.
Cross-border treatment flows between Australia and New Zealand remain small and are driven mainly by donor availability rather than price.
Supply Chain & Raw Material Dynamics: Australia & New Zealand Fertility Services Market
Input Dependency Map
Input
Typical Origin
Price Trend Direction
Supply Risk
Embryo culture media
Denmark, Sweden, United States
Up 2–5% annually
High
Recombinant FSH and GnRH antagonists
Europe, United States
Up 3–6% annually
Medium
Vitrification and cryopreservation devices
United States, Japan
Stable to up
Medium
Liquid nitrogen
Domestic industrial gas suppliers
Volatile with energy prices
Low
ICSI micropipettes and catheters
Germany, Japan
Up 1–4% annually
Medium
Upstream Dependencies
The Culture Media Market is the most concentrated upstream link: a small number of global suppliers serve nearly all accredited ANZ laboratories, and switching requires full protocol revalidation.
The Cryopreservation Equipment Market depends on liquid nitrogen logistics and on time-lapse incubator hardware, both of which carry long replacement lead times.
Gonadotropin supply is dual-sourced in most networks, but tender cycles still transmit global API pricing directly into clinic cost per cycle.
Historical Disruption Patterns
Pandemic-era freight disruption extended media lead times from weeks to several months and forced clinics to hold buffer stock, a practice most have retained.
Energy price spikes raise liquid nitrogen and cold-chain electricity costs simultaneously, hitting cryostorage-heavy clinics hardest.
Regulatory & Policy Landscape: Australia & New Zealand Fertility Services Market
Framework Comparison
Geography
Lead Framework or Body
Key Compliance Requirement
Recent Direction
Australia
NHMRC ethical guidelines on ART and RTAC accreditation
Laboratory accreditation, donor record retention, embryo storage limits
Tightening quality and consent documentation
New Zealand
Human Assisted Reproductive Technology Act and Ministry of Health oversight
Eligibility criteria for publicly funded cycles, gamete donor rules
Stable with periodic funding review
Europe
ESHRE guidance and EU MDR for devices
Device conformity, traceability, data protection
Increasing device documentation burden
North America
FDA device oversight and CDC ART reporting
Mandatory cycle reporting and laboratory inspection
Consistent enforcement
Standards and Compliance Impact
Accreditation under RTAC remains the gatekeeper for Australian clinics, and ISO 15189 laboratory quality standards underpin most private network operating models.
Device-side compliance follows ISO 13485 and, for European exports, EU MDR conformity, which lengthens hardware approval timelines.
Australia's AASB S2 climate disclosure requirements from 1 January 2025 add reporting obligations for large listed fertility groups.
Donor consent, record retention and gamete import rules are the policy areas most likely to raise operating cost per cycle.
Australia & New Zealand Fertility Services Market Segmentation
1. Procedure
1.1. IVF with ICSI
1.2. IUI
1.3. IVF without ICSI
1.4. Surrogacy
1.5. Others
2. Service
2.1. Fresh Non-Donor
2.2. Frozen Non-Donor
2.3. Egg & Embryo Banking
2.4. Fresh Donor
2.5. Frozen Donor
3. End User
3.1. Fertility Clinics
3.2. Hospitals
3.3. Surgical Centers
3.4. Clinical Research Institutes
Australia & New Zealand Fertility Services Market Segmentation By Geography
1. North America
1.1. United States
1.2. Canada
1.3. Mexico
2. South America
2.1. Brazil
2.2. Argentina
2.3. Rest of South America
3. Europe
3.1. United Kingdom
3.2. Germany
3.3. France
3.4. Italy
3.5. Spain
3.6. Russia
3.7. Benelux
3.8. Nordics
3.9. Rest of Europe
4. Middle East & Africa
4.1. Turkey
4.2. Israel
4.3. GCC
4.4. North Africa
4.5. South Africa
4.6. Rest of Middle East & Africa
5. Asia Pacific
5.1. China
5.2. India
5.3. Japan
5.4. South Korea
5.5. ASEAN
5.6. Oceania
5.7. Rest of Asia Pacific
Australia & New Zealand Fertility Services Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 4.6% from 2020-2034
Segmentation
By Procedure
IVF with ICSI
IUI
IVF without ICSI
Surrogacy
Others
By Service
Fresh Non-Donor
Frozen Non-Donor
Egg & Embryo Banking
Fresh Donor
Frozen Donor
By End User
Fertility Clinics
Hospitals
Surgical Centers
Clinical Research Institutes
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
United Kingdom
Germany
France
Italy
Spain
Russia
Benelux
Nordics
Rest of Europe
Middle East & Africa
Turkey
Israel
GCC
North Africa
South Africa
Rest of Middle East & Africa
Asia Pacific
China
India
Japan
South Korea
ASEAN
Oceania
Rest of Asia Pacific
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Procedure
5.1.1. IVF with ICSI
5.1.2. IUI
5.1.3. IVF without ICSI
5.1.4. Surrogacy
5.1.5. Others
5.2. Market Analysis, Insights and Forecast - by Service
5.2.1. Fresh Non-Donor
5.2.2. Frozen Non-Donor
5.2.3. Egg & Embryo Banking
5.2.4. Fresh Donor
5.2.5. Frozen Donor
5.3. Market Analysis, Insights and Forecast - by End User
5.3.1. Fertility Clinics
5.3.2. Hospitals
5.3.3. Surgical Centers
5.3.4. Clinical Research Institutes
5.4. Market Analysis, Insights and Forecast - by Region
5.4.1. North America
5.4.2. South America
5.4.3. Europe
5.4.4. Middle East & Africa
5.4.5. Asia Pacific
6. North America Market Analysis, Insights and Forecast, 2020-2034
6.1. Market Analysis, Insights and Forecast - by Procedure
6.1.1. IVF with ICSI
6.1.2. IUI
6.1.3. IVF without ICSI
6.1.4. Surrogacy
6.1.5. Others
6.2. Market Analysis, Insights and Forecast - by Service
6.2.1. Fresh Non-Donor
6.2.2. Frozen Non-Donor
6.2.3. Egg & Embryo Banking
6.2.4. Fresh Donor
6.2.5. Frozen Donor
6.3. Market Analysis, Insights and Forecast - by End User
6.3.1. Fertility Clinics
6.3.2. Hospitals
6.3.3. Surgical Centers
6.3.4. Clinical Research Institutes
7. South America Market Analysis, Insights and Forecast, 2020-2034
7.1. Market Analysis, Insights and Forecast - by Procedure
7.1.1. IVF with ICSI
7.1.2. IUI
7.1.3. IVF without ICSI
7.1.4. Surrogacy
7.1.5. Others
7.2. Market Analysis, Insights and Forecast - by Service
7.2.1. Fresh Non-Donor
7.2.2. Frozen Non-Donor
7.2.3. Egg & Embryo Banking
7.2.4. Fresh Donor
7.2.5. Frozen Donor
7.3. Market Analysis, Insights and Forecast - by End User
7.3.1. Fertility Clinics
7.3.2. Hospitals
7.3.3. Surgical Centers
7.3.4. Clinical Research Institutes
8. Europe Market Analysis, Insights and Forecast, 2020-2034
8.1. Market Analysis, Insights and Forecast - by Procedure
8.1.1. IVF with ICSI
8.1.2. IUI
8.1.3. IVF without ICSI
8.1.4. Surrogacy
8.1.5. Others
8.2. Market Analysis, Insights and Forecast - by Service
8.2.1. Fresh Non-Donor
8.2.2. Frozen Non-Donor
8.2.3. Egg & Embryo Banking
8.2.4. Fresh Donor
8.2.5. Frozen Donor
8.3. Market Analysis, Insights and Forecast - by End User
8.3.1. Fertility Clinics
8.3.2. Hospitals
8.3.3. Surgical Centers
8.3.4. Clinical Research Institutes
9. Middle East & Africa Market Analysis, Insights and Forecast, 2020-2034
9.1. Market Analysis, Insights and Forecast - by Procedure
9.1.1. IVF with ICSI
9.1.2. IUI
9.1.3. IVF without ICSI
9.1.4. Surrogacy
9.1.5. Others
9.2. Market Analysis, Insights and Forecast - by Service
9.2.1. Fresh Non-Donor
9.2.2. Frozen Non-Donor
9.2.3. Egg & Embryo Banking
9.2.4. Fresh Donor
9.2.5. Frozen Donor
9.3. Market Analysis, Insights and Forecast - by End User
9.3.1. Fertility Clinics
9.3.2. Hospitals
9.3.3. Surgical Centers
9.3.4. Clinical Research Institutes
10. Asia Pacific Market Analysis, Insights and Forecast, 2020-2034
10.1. Market Analysis, Insights and Forecast - by Procedure
10.1.1. IVF with ICSI
10.1.2. IUI
10.1.3. IVF without ICSI
10.1.4. Surrogacy
10.1.5. Others
10.2. Market Analysis, Insights and Forecast - by Service
10.2.1. Fresh Non-Donor
10.2.2. Frozen Non-Donor
10.2.3. Egg & Embryo Banking
10.2.4. Fresh Donor
10.2.5. Frozen Donor
10.3. Market Analysis, Insights and Forecast - by End User
10.3.1. Fertility Clinics
10.3.2. Hospitals
10.3.3. Surgical Centers
10.3.4. Clinical Research Institutes
11. Competitive Analysis
11.1. Company Profiles
11.1.1. MONASH IVF GROUP LIMITED
11.1.1.1. Company Overview
11.1.1.2. Products
11.1.1.3. Company Financials
11.1.1.4. SWOT Analysis
11.1.2. FERTILITY ASSOCIATES LIMITED
11.1.2.1. Company Overview
11.1.2.2. Products
11.1.2.3. Company Financials
11.1.2.4. SWOT Analysis
11.1.3. FERTILITY SA
11.1.3.1. Company Overview
11.1.3.2. Products
11.1.3.3. Company Financials
11.1.3.4. SWOT Analysis
11.1.4. NATIONAL WOMEN’S HEALTH
11.1.4.1. Company Overview
11.1.4.2. Products
11.1.4.3. Company Financials
11.1.4.4. SWOT Analysis
11.1.5. GENEA LIMITED
11.1.5.1. Company Overview
11.1.5.2. Products
11.1.5.3. Company Financials
11.1.5.4. SWOT Analysis
11.1.6. CITY FERTILITY
11.1.6.1. Company Overview
11.1.6.2. Products
11.1.6.3. Company Financials
11.1.6.4. SWOT Analysis
11.1.7. ADORA FERTILITY
11.1.7.1. Company Overview
11.1.7.2. Products
11.1.7.3. Company Financials
11.1.7.4. SWOT Analysis
11.1.8. FERTILITY FIRST
11.1.8.1. Company Overview
11.1.8.2. Products
11.1.8.3. Company Financials
11.1.8.4. SWOT Analysis
11.1.9. VIRTUS HEALTH
11.1.9.1. Company Overview
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. CARE FERTILITY
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
12. Research Methodology
List of Figures
Figure 1: Australia & New Zealand Fertility Services Market Revenue Breakdown (million, %) by Product 2026 & 2034
Figure 2: Australia & New Zealand Fertility Services Market Value Share (%), by Procedure 2026 & 2034
Figure 3: Australia & New Zealand Fertility Services Market Value Share (%), by Service 2026 & 2034
Figure 4: Australia & New Zealand Fertility Services Market Value Share (%), by End User 2026 & 2034
Figure 5: Australia & New Zealand Fertility Services Market Share (%) by Company 2026
List of Tables
Table 1: Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 2: Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 3: Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 4: Australia & New Zealand Fertility Services Market Revenue million Forecast, by Region 2020 & 2034
Table 5: North America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 6: North America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 7: North America Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 8: North America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Country 2020 & 2034
Table 9: United States Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 10: Canada Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 11: Mexico Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 12: South America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 13: South America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 14: South America Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 15: South America Australia & New Zealand Fertility Services Market Revenue million Forecast, by Country 2020 & 2034
Table 16: Brazil Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 17: Argentina Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 18: Rest of South America Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 19: Europe Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 20: Europe Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 21: Europe Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 22: Europe Australia & New Zealand Fertility Services Market Revenue million Forecast, by Country 2020 & 2034
Table 23: United Kingdom Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 24: Germany Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 25: France Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 26: Italy Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 27: Spain Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 28: Russia Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 29: Benelux Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 30: Nordics Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 31: Rest of Europe Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 32: Middle East & Africa Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 33: Middle East & Africa Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 34: Middle East & Africa Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 35: Middle East & Africa Australia & New Zealand Fertility Services Market Revenue million Forecast, by Country 2020 & 2034
Table 36: Turkey Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 37: Israel Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 38: GCC Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 39: North Africa Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 40: South Africa Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 41: Rest of Middle East & Africa Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 42: Asia Pacific Australia & New Zealand Fertility Services Market Revenue million Forecast, by Procedure 2020 & 2034
Table 43: Asia Pacific Australia & New Zealand Fertility Services Market Revenue million Forecast, by Service 2020 & 2034
Table 44: Asia Pacific Australia & New Zealand Fertility Services Market Revenue million Forecast, by End User 2020 & 2034
Table 45: Asia Pacific Australia & New Zealand Fertility Services Market Revenue million Forecast, by Country 2020 & 2034
Table 46: China Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 47: India Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 48: Japan Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 49: South Korea Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 50: ASEAN Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 51: Oceania Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Table 52: Rest of Asia Pacific Australia & New Zealand Fertility Services Market Revenue (million) Forecast, by Application 2020 & 2034
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Primary research accounts for 70–80% of all data points, with secondary validation covering the remaining 20–30% of inputs used in this Australia & New Zealand Fertility Services Market study.
Direct interviews and structured surveys were conducted with five distinct company types across the fertility value chain: multi-site private IVF clinic operators running accredited embryology laboratories in Australia and New Zealand; cryopreservation and vitrification equipment OEMs supplying time-lapse incubators, liquid nitrogen storage and vitrification devices; embryo culture media and single-use IVF consumables suppliers including pipette, catheter and hyaluronidase vendors; donor gamete and sperm bank operators plus third-party reproduction intermediaries; and reproductive genetics laboratories delivering preimplantation genetic testing and karyotyping.
Respondents were screened to include the following stakeholder designations: Medical Director, Reproductive Endocrinology and Infertility; Scientific Director, Embryology and Andrology Laboratory; Group Procurement Manager, IVF Consumables and Cold-Chain Logistics; and Clinical Operations Manager, Multi-Site Fertility Network.
Secondary research draws on standard financial and transaction databases: Bloomberg, Factiva, Hoovers and PitchBook, used for company financials, ownership structures and M&A comparables.
Trade associations, professional societies and peer-reviewed journals are used for procedure mix, laboratory standards and reimbursement context. No commercial market research websites are cited as primary sources.
Every report is updated to the date of purchase; all figures, company events and regulatory references reflect the latest available information at the moment of delivery.
Demand Modeling & Market Estimation
Top-down and bottom-up methodologies are applied simultaneously and validated through multi-level data triangulation across procedure, service, end-user and country levels.
The bottom-up build relies on specific quantitative metrics: the number of ART treatment cycles performed annually per accredited clinic; average revenue per stimulated IVF cycle in AUD split by procedure (ICSI versus non-ICSI) and service line; the number of RTAC-accredited fertility clinics and diagnostic laboratories across Australia and New Zealand; and average consumable and pharmaceutical cost per stimulated cycle covering culture media, gonadotropins and vitrification kits.
The top-down build starts from regional assisted reproductive technology spending, then applies procedure mix shares, service-line splits and end-user allocation to isolate the ANZ scope.
Segment forecasts, including the IVF with ICSI, IUI and donor service lines, are cross-checked against clinic-level capacity constraints so that modelled growth cannot exceed accredited laboratory throughput.
Data Accuracy & Quality Check
The study carries a guaranteed estimated data accuracy level of 85–90%, verified through independent re-derivation of key figures by a second analyst team.
Triangulation reconciles survey responses, financial disclosures, government statistics and trade data; variances above 5% trigger a targeted re-interview.
Currency, base-year and forecast-period assumptions are standardised, and all segment shares are constrained to sum to 100% at each level of the model.
Final outputs are reviewed for internal consistency between the regional chart, segment matrices and the narrative before publication, and the dataset is refreshed to the customer's purchase date.
Frequently Asked Questions
1. How did Australia and New Zealand fertility treatment demand change after the COVID-19 pandemic?
Fresh cycle volumes dropped by roughly 12–15% during 2020 lockdowns as clinics suspended stimulation protocols, then recovered within four quarters. By 2023 the region recorded more assisted reproduction cycles than in 2019, and ANZ clinics now deliver around 100,000 cycles a year across Australia alone. The durable structural shift is toward frozen embryo transfer, telehealth monitoring and home-based hormone dosing, which roughly 60% of Australian clinics retain as standard practice.
2. What raw materials and inputs are critical to the Australia & New Zealand Fertility Services Market supply chain?
Embryo culture media, vitrification kits, recombinant FSH, GnRH antagonists, hyaluronidase, ICSI micropipettes and liquid nitrogen are the core inputs. More than 80% of culture media and vitrification consumables used in ANZ clinics are imported, mainly from Denmark, Sweden and the United States. A single supplier disruption can lift consumable costs by 6–9% within two quarters because accredited laboratories cannot substitute media without revalidating their protocols.
3. Which region leads the global fertility services industry and why?
Asia-Pacific holds the largest share at approximately 34–35% of global fertility services revenue, driven by treatment volume in China, India and Japan and by rapid private-clinic expansion. Europe follows at about 26%, supported by broad public reimbursement in France, Spain and the Nordics. North America accounts for roughly 23%, where high average revenue per cycle rather than volume anchors value.
4. How do import and export flows shape fertility service delivery in Australia and New Zealand?
ANZ is a net importer of fertility inputs: imports cover more than 85% of culture media, vitrification devices and gonadotropin pharmaceuticals, with Australia drawing most supply from the EU and the United States. Export activity is limited to clinical training, embryology consultancy and a small volume of cross-border patient travel rather than physical goods. This imbalance exposes clinic margins to freight costs and to AUD/NZD currency swings on euro- and USD-denominated contracts.
5. What sustainability and ESG factors are reshaping fertility clinics in Australia and New Zealand?
Cold-chain energy use, liquid nitrogen consumption and single-use plastics dominate the sector footprint, with laboratory consumables and cryostorage estimated to generate 55–65% of a clinic's clinical waste stream. Australia's AASB S2 climate disclosure standard applies to large entities from 1 January 2025, pushing listed clinic groups toward scope 1 and 2 emissions reporting. Several ANZ networks are trialling nitrogen recovery systems and media reagent sharing to cut both cost and waste.
6. What are the biggest restraints and supply-chain risks facing the Australia & New Zealand Fertility Services Market?
Out-of-pocket cost is the primary restraint, with a self-funded IVF cycle in Australia typically running AUD 8,000–12,000 after Medicare and safety-net rebates. Embryologist and sonographer shortages cap how fast accredited laboratories can add capacity, and New Zealand public funding covers only a defined number of cycles per eligible couple. Import dependence for media and gonadotropins adds a further layer of price and continuity risk.
.jpg){kind=small}
